Acadian Asset Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Acadian Asset Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-189,866	Closed	-$596K	–	2109
2019 Q2	$596K	Sell	189,866 -847,980	-82%	-$2.75M	﹤0.01%	961
2019 Q1	$3.86M	Sell	1,037,846 -1,244,873	-55%	-$4.2M	0.02%	506
2018 Q4	$6.62M	Sell	2,282,719 -514,485	-18%	-$1.41M	0.03%	335
2018 Q3	$7.36M	Sell	2,797,204 -1,202,454	-30%	-$2.95M	0.03%	325
2018 Q2	$9.36M	Sell	3,999,658 -749,801	-16%	-$2.09M	0.04%	305
2018 Q1	$14M	Sell	4,749,459 -531,829	-10%	-$1.45M	0.06%	242
2017 Q4	$14.5M	Hold	5,281,288	–	–	0.06%	236
2017 Q3	$17.9M	Buy	5,281,288 +458,356	+10%	+$1.27M	0.08%	209
2017 Q2	$11.9M	Sell	4,822,932 -2,756	-0.1%	-$6.34K	0.05%	260
2017 Q1	$11M	Sell	4,825,688 -677,597	-12%	-$1.5M	0.05%	271
2016 Q4	$11.7M	Sell	5,503,285 -592,640	-10%	-$1.65M	0.06%	263
2016 Q3	$20.4M	Sell	6,095,925 -139,899	-2%	-$444K	0.1%	183
2016 Q2	$19.6M	Buy	6,235,824 +156,534	+3%	+$522K	0.1%	179
2016 Q1	$20.2M	Sell	6,079,290 -76,160	-1%	-$237K	0.1%	197
2015 Q4	$21.8M	Buy	6,155,450 +2,597,425	+73%	+$10.9M	0.11%	193
2015 Q3	$17.9M	Sell	3,558,025 -1,129,948	-24%	-$6.47M	0.1%	206
2015 Q2	$30.1M	Sell	4,687,973 -1,767,611	-27%	-$11.8M	0.15%	164
2015 Q1	$45.4M	Buy	6,455,584 +483,911	+8%	+$3.5M	0.21%	135
2014 Q4	$46M	Sell	5,971,673 -621,771	-9%	-$4.92M	0.21%	132
2014 Q3	$49.3M	Buy	6,593,444 +106,432	+2%	+$988K	0.24%	120
2014 Q2	$62.8M	Buy	6,487,012 +885,500	+16%	+$7.89M	0.31%	86
2014 Q1	$46.5M	Sell	5,601,512 -114,060	-2%	-$978K	0.24%	101
2013 Q4	$48.2M	Buy	5,715,572 +91,195	+2%	+$769K	0.27%	92
2013 Q3	$44.8M	Sell	5,624,377 -37,806	-0.7%	-$304K	0.29%	94
2013 Q2	$43.7M	Buy	+5,662,183	New	+$44.2M	0.3%	91

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Acadian Asset Management's PDLI Position: Q3 2019 in Review

Acadian Asset Management sold out of PDL BioPharma, Inc. (PDLI) in Q3 2019, closing a stake of 189,866 shares — an estimated $596K sold.

Acadian Asset Management first reported a position in PDLI in Q2 2013 and held it in 25 quarters. The position peaked at $62.8M in Q2 2014. 140 funds tracked by Wall St. Rank hold PDLI as of Q3 2019.

Acadian Asset Management reported no remaining PDL BioPharma, Inc. position as of Q3 2019 after selling out during the quarter.
Acadian Asset Management sold 189,866 PDL BioPharma, Inc. shares in Q3 2019, an estimated $596K.
Acadian Asset Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 25 quarters.
Acadian Asset Management's PDL BioPharma, Inc. position peaked at $62.8M in Q2 2014.
140 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2019.

Based on Acadian Asset Management's 13F filing for Q3 2019, filed 7 Nov 2019.